Aquestive Therapeutics, Inc.

NasdaqGM:AQST 주식 보고서

시가총액: US$502.6m

Aquestive Therapeutics 관리

관리 기준 확인 2/4

Aquestive Therapeutics CEO는 Dan Barber, May2022 에 임명되었습니다 의 임기는 2.5 년입니다. 총 연간 보상은 $ 2.50M, 24% 로 구성됩니다. 24% 급여 및 76% 보너스(회사 주식 및 옵션 포함). 는 $ 7.64M 가치에 해당하는 회사 주식의 1.52% 직접 소유합니다. 7.64M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 2.4 년입니다.

주요 정보

Dan Barber

최고 경영자

US$2.5m

총 보상

CEO 급여 비율24.0%
CEO 임기2.5yrs
CEO 소유권1.5%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간2.4yrs

최근 관리 업데이트

Recent updates

Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher

Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025

Aug 20

Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic

What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless

Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024

Apr 09

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up

Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1

Jan 19

Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement

Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction

Oct 11

Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film

Sep 28

Aquestive Therapeutics: FDA Stymies Libervant Launch

Sep 05

Aquestive Therapeutics: A First Take

Aug 29

CEO 보상 분석

Dan Barber 의 보수는 Aquestive Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Jun 30 2024n/an/a

-US$26m

Mar 31 2024n/an/a

-US$29m

Dec 31 2023US$2mUS$600k

-US$8m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$23m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$1mUS$542k

-US$54m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$73m

Mar 31 2022n/an/a

-US$69m

Dec 31 2021US$1mUS$424k

-US$71m

Sep 30 2021n/an/a

-US$62m

Jun 30 2021n/an/a

-US$64m

Mar 31 2021n/an/a

-US$54m

Dec 31 2020US$840kUS$410k

-US$56m

Sep 30 2020n/an/a

-US$48m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$1mUS$389k

-US$66m

Sep 30 2019n/an/a

-US$68m

Jun 30 2019n/an/a

-US$64m

Mar 31 2019n/an/a

-US$80m

Dec 31 2018US$2mUS$319k

-US$61m

Sep 30 2018n/an/a

-US$61m

Jun 30 2018n/an/a

-US$38m

Mar 31 2018n/an/a

-US$8m

Dec 31 2017US$899kUS$300k

-US$14m

보상 대 시장: Dan 의 총 보상 ($USD 2.50M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.42M ).

보상과 수익: 회사가 수익성이 없는 동안 Dan 의 보상이 증가했습니다.

CEO

Dan Barber (48 yo)

2.5yrs

테뉴어

US$2,496,141

보상

Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...

리더십 팀

이름위치테뉴어보상소유권
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 7.6m
A. Toth
Chief Financial Officer3.9yrsUS$1.12m0.43%
$ 2.1m
Lori Braender
General Counsel6.2yrsUS$1.19m0.52%
$ 2.6m
Cassie Jung
Chief Operating Officer2yrs데이터 없음0.25%
$ 1.3m
Alexander Schobel
Chief Innovation & Technology Officer9.9yrsUS$810.02k1.08%
$ 5.4m
Stephen Wargacki
Chief Science Officerno data데이터 없음0.28%
$ 1.4m
Sherry Korczynski
Senior Vice President of Sales & Marketingless than a year데이터 없음0.027%
$ 138.0k
Peter Boyd
Senior Vice President of Information Technology & Human Resources1.7yrs데이터 없음0.26%
$ 1.3m
Gary Slatko
Chief Medical Officerno data데이터 없음데이터 없음
Carl Kraus
Chief Medical Officer1.4yrs데이터 없음0.28%
$ 1.4m
Robert Arnold
VP of Financeno data데이터 없음데이터 없음

2.3yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 관리: AQST 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Daniel Barber
CEO, President & Director2.5yrsUS$2.50m1.52%
$ 7.6m
Santo Costa
Independent Director8.9yrsUS$202.16k0.019%
$ 95.7k
Timothy Morris
Independent Director2.3yrsUS$145.23k0%
$ 0
Gregory Brown
Independent Chairman of the Board17.7yrsUS$150.77k0.082%
$ 414.5k
Julie Krop
Independent Director3.8yrsUS$137.69k0%
$ 0
John Cochran
Independent Vice Chairman of the Board20.8yrsUS$137.23k0.11%
$ 549.1k
Marco Taglietti
Independent Director3.8yrsUS$121.78k0%
$ 0
Carlos Camargo
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
Ruchi Gupta
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
David Bernstein
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
David Fleischer
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음
Matthew Greenhawt
Member of Scientific Advisory Board2.2yrs데이터 없음데이터 없음

2.4yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: AQST 의 이사회는 경험(평균 재직 기간 2.4 년)으로 간주되지 않으므로 새 이사회가 필요합니다.